Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
McKesson
Dow
Medtronic
Moodys

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 9,662,377

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,662,377
Title:Therapeutic composition for treatment of glioblastoma
Abstract: The present invention is directed to compositions and methods for treating an animal diagnosed with Glioblastoma multiforme (GBM).
Inventor(s): Olin; Michael Raymond (Minneapolis, MN), Ohlfest; John R. (Minneapolis, MN), Low; Walter (Minneapolis, MN)
Assignee: REGENTS OF THE UNIVERSITY OF MINNEOSTA (Minneapolis, MN)
Application Number:15/135,292
Patent Claims:1. A method of eliciting an immune response in an animal in need thereof, comprising administering to the animal an anti-tumor composition comprising an adherent glioblastoma GBM6-AD stem cell, wherein the adherent glioblastoma GBM6-AD stem cell is ATCC.RTM. Patent Deposit Designation PTA-11498.

2. The method of claim 1, further comprising administering Imiquimod to the animal.

3. The method of claim 2, wherein the Imiquimod is administered topically, intradermally, subcutaneously, and/or via intralymph node injections.

4. The method of claim 1, wherein the anti-tumor composition is administered parenterally, orally or intranasally.

5. The method of claim 1, wherein the anti-tumor composition is administered at more than one time point.

6. The method of claim 1, wherein the anti-tumor composition is administered at a dose of 100,000-100 million GBM6-AD cells at each administration time point.

7. The method of claim 1, further comprising administering irradiation therapy to the animal.

8. The method of claim 7, wherein the irradiation therapy is administered at a dose of less than 6,000 cGY.

9. The method of claim 7, further comprising administering a radiation sensitizer to the animal.

10. The method of claim 9, wherein the radiation sensitizer is a parp inhibitor or temozolomide.

11. The method of claim 1, wherein the animal is a mammal.

12. The method of claim 1, further comprising administering dexamethasone therapy to the animal.

13. The method of claim 12, wherein the dexamethasone therapy is administered at the time of diagnosis.

14. The method of claim 1, further comprising administering a chemotherapy or drug that depletes regulatory T cell or myeloid derived suppressor cells.

15. The method of claim 14, wherein the chemotherapy is sunititib, ontak, cyclophosphamide, gemcitabine, and/or retionoic acid.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Merck
Johnson and Johnson
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.